This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Partin, A. W. Articles by Coffey, D. S. Search for Related Content PubMed PubMed Citation Articles by Partin, A. W. Articles by Coffey, D. S.

Nuclear Matrix Protein Patterns in Human Benign Prostatic Hyperplasia and Prostate Cancer¹

Departments of Urology, Pathology, and Oncology, The Johns Hopkins University School of Medicine and the James Buchanan Brady Urological Institute, The Johns Hopkins Hospital, Baltimore, Maryland 21205

The nuclear matrix represents the structural component of the nucleus that determines nuclear shape and higher order DNA organization. We have previously shown tissue specificity in nuclear matrix proteins (NMP), in rat sex accessory tissues, and in a rat model of prostate cancer. This study compares NMP patterns for fresh human normal prostate, benign prostatic hyperplasia (BPH), and prostate cancer for 21 men undergoing surgery for clinically localized prostate cancer or BPH. NMP patterns were compared using high resolution two-dimensional polyacrylamide gel electrophoresis. We identified by molecular weight and isoelectric point 14 different proteins that were consistently present or absent among the various tissues. One protein (PC-1), a M_r 56,000 protein with an isoelectric point of 6.58, appeared in 14 of 14 different nuclear matrix preparations from prostate cancer and was not detected in normal prostate (0 of 13) or BPH (0 of 14). The NMP patterns are consistent with a model of disease progression in which BPH shares many of the nuclear matrix changes observed in prostate cancer.

¹ This work was supported by SPORE Grants P50 CA 58236-01 (National Cancer Institute), DK-19300 (National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases), and CA 15416 (National Cancer Institute).

Received 12/ 4/92. Accepted 1/12/93.

This article has been cited by other articles:

				M. E. Wright, D. K. Han, and R. Aebersold Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer Mol. Cell. Proteomics, April 1, 2005; 4(4): 545 - 554. [Abstract] [Full Text] [PDF]

				H. B. Grossman, E. Messing, M. Soloway, K. Tomera, G. Katz, Y. Berger, and Y. Shen Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay JAMA, February 16, 2005; 293(7): 810 - 816. [Abstract] [Full Text] [PDF]

				J. D. Debes, T. J. Sebo, H. V. Heemers, B. R. Kipp, D. A. L. Haugen, C. M. Lohse, and D. J. Tindall p300 Modulates Nuclear Morphology in Prostate Cancer Cancer Res., February 1, 2005; 65(3): 708 - 712. [Abstract] [Full Text] [PDF]

				J. Sagara, T. Higuchi, Y. Hattori, M. Moriya, H. Sarvotham, H. Shima, H. Shirato, K. Kikuchi, and S. Taniguchi Scapinin, a Putative Protein Phosphatase-1 Regulatory Subunit Associated with the Nuclear Nonchromatin Structure J. Biol. Chem., November 14, 2003; 278(46): 45611 - 45619. [Abstract] [Full Text] [PDF]

				M. Kasai, J. Guerrero-Santoro, R. Friedman, E. S. Leman, R. H. Getzenberg, and D. B. DeFranco The Group 3 LIM Domain Protein Paxillin Potentiates Androgen Receptor Transactivation in Prostate Cancer Cell Lines Cancer Res., August 15, 2003; 63(16): 4927 - 4935. [Abstract] [Full Text] [PDF]

				D. S. Coffey Nuclear Matrix Proteins as Proteomic Markers of Preneoplastic and Cancer Lesions : Commentary re: G. Brunagel et al., Nuclear Matrix Protein Alterations Associated with Colon Cancer Metastasis to the Liver. Clin. Cancer Res., 8: 3039-3045, 2002. Clin. Cancer Res., October 1, 2002; 8(10): 3031 - 3033. [Full Text] [PDF]

				C. A. Heinlein and C. Chang Androgen Receptor (AR) Coregulators: An Overview Endocr. Rev., April 1, 2002; 23(2): 175 - 200. [Abstract] [Full Text] [PDF]

				G. Brunagel, B. N. Vietmeier, A. J. Bauer, R. E. Schoen, and R. H. Getzenberg Identification of Nuclear Matrix Protein Alterations Associated with Human Colon Cancer Cancer Res., April 1, 2002; 62(8): 2437 - 2442. [Abstract] [Full Text] [PDF]

				N. Takaha, A. L. Hawkins, C. A. Griffin, W. B. Isaacs, and D. S. Coffey High Mobility Group Protein I(Y): A Candidate Architectural Protein for Chromosomal Rearrangements in Prostate Cancer Cells Cancer Res., February 1, 2002; 62(3): 647 - 651. [Abstract] [Full Text] [PDF]

				S. M. Townson, T. Sullivan, Q. Zhang, G. M. Clark, C. K. Osborne, A. V. Lee, and S. Oesterreich HET/SAF-B Overexpression Causes Growth Arrest and Multinuclearity and Is Associated with Aneuploidy in Human Breast Cancer Clin. Cancer Res., September 1, 2000; 6(9): 3788 - 3796. [Abstract] [Full Text]

				B. R. Konety, T.-S. T. Nguyen, R. Dhir, R. S. Day, M. J. Becich, W. M. Stadler, and R. H. Getzenberg Detection of Bladder Cancer Using a Novel Nuclear Matrix Protein, BLCA-4 Clin. Cancer Res., July 1, 2000; 6(7): 2618 - 2625. [Abstract] [Full Text]

				L. Yang, J. Guerrero, H. Hong, D. B. DeFranco, and M. R. Stallcup Interaction of the tau 2 Transcriptional Activation Domain of Glucocorticoid Receptor with a Novel Steroid Receptor Coactivator, Hic-5, Which Localizes to Both Focal Adhesions and the Nuclear Matrix Mol. Biol. Cell, June 1, 2000; 11(6): 2007 - 2018. [Abstract] [Full Text]

				A. Raziuddin, D. Court, F. H. Sarkar, Y.-L. Liu, H.-f. Kung, and R. Raziuddin A c-erbB-2 Promoter-specific Nuclear Matrix Protein from Human Breast Tumor Tissues Mediates NF-kappa B DNA Binding Activity J. Biol. Chem., June 20, 1997; 272(25): 15715 - 15720. [Abstract] [Full Text] [PDF]